VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials.
VeriSIM Life has raised $15.0M in total funding. The most recent round was Series A. The last funding was announced in January 2022.
VeriSIM Life's investors include National Science Foundation, Village Global, Susa Ventures, Amplify Partners, Intel Capital.
VeriSIM Life is headquartered in San Francisco, United States.
VeriSIM Life is a computational bioplatform that predicts the clinical outcomes of new drugs before clinical trials.
VeriSIM Life is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"VeriSIM Life — Funding & Investors." VCBacked, January 13, 2022, https://www.vcbacked.co/company/verisim-life. Accessed September 2, 2026.
VCBacked. (2022). VeriSIM Life — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/verisim-life
{{cite web |title=VeriSIM Life — Funding & Investors |url=https://www.vcbacked.co/company/verisim-life |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated